Virodynamic predictors of response to pegylated interferon and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1029-1037

  Mihm, Ulriker ^a   Chan, Henry Lik Yuen ^b   Zeuzem, Stefan ^a   Chim, Angel Mei Ling ^b   Hui, Alex Yui ^b   Wong, Vincent Wai Sun ^b   Sung, Joseph Jao Yiu ^b   Herrmann, Eva ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MATHEMATICAL MODEL; MICROBIAL KINETICS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SEROCONVERSION; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; VIRAL LOAD;

EID: 58149496652     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
4. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
5. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129.
6. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
7. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
9. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357-1364.
10. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-187.
11. Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32:626-629.
12. Neumann AU, Lam NP, Dahari H, Boehme R, Thomas AC, McDade H. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
13. Mihm U, Gartner BC, Faust D, et al. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 2005; 43:217-224.
14. Sypsa VA, Mimidis K, Tassopoulos NC, et al. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology 2005; 42:77-85.
15. ter Borg MJ, Hansen BE, Herrmann E, et al. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B. Antivir Ther 2007; 12:1285-1294.
16. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylared interferon alfa-2b. Semin Liver Dis 2003; 23 Suppl 1:13-18.
17. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398-4402.
18. Lau GK, Tsiang M, Hou J, et al. Combination therapy with lamivudine an famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32:394-399.
19. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34:1012-1020.
20. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863-1869.
21. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002; 22:121-126.
22. Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002; 14:1007-1011.
23. Wolters LM, Hansen BE, Niesters HG, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002; 37:253-258.
24. Wolters LM, Hansen BE, Niesters HG, Dehertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37:137-144.
25. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35.
26. Colombatto P, Civitano L, Bizzarri R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 2006; 11:197-212.
27. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
28. Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sunj JJ. Early hepatitis B virus DNA suppression can predict virological response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008. 6:1022-1026.
29. Farci P, Marcellin P, Lu ZM, et al. On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alfa-2a (40 kDa) (Pegasys®). J Hepatol 2005; 42 Suppl 2:175.
30. Fried MW, Piratvisuth T. Lau,GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434.
31. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44:721-727.
32. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6:167-172.
33. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427.